Into This World We're Thrown
NCT05363605
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: FGFR
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions:
https://ClinicalTrials.gov/show/NCT05363605
NCT05242822
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: FGFR
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients must have tumors that express an FGFR2 and/or FGFR3 gene alteration
Exclusions: Patients with known clinically-active or clinically-progressive brain metastases
https://ClinicalTrials.gov/show/NCT05242822